SPANI SH B O-E BIOI UR N O D P U MB E S HAM E 2 R T 0 1 R

SPANISH BIOINDUSTRY ASSO

CIA

TIO

N PA

VILIO

NBIO-EUROPE 2019NOVEMBER 11-13, 2019HAMBURG, GERM

AN

Y

Spanish Bioindustry Association

10th International Meeting on BiotechnologySeptember 29th – October 1st, 2020

Pamplona, Spain

www.biospain2020.org

FUE

NT

E: A

YU

NTA

MIE

NT

O D

E P

AM

PLO

NA

-IR

UÑ

A.

ORGANIZED BY:


+750 licensing opportunities

1.550 attendees

200 exhibitors

+40 sessions

54 investors

3.330 one-to-one meetings

31 countries represented

3rd largest biotech partnering event in Europe

Dámaso Molero, [email protected]ígono Mocholi C/Mocholi 2, 31110 Noáin, (Navarra) Spainwww.linkedin.com/company/3p-biopharmaceuticals/@3PBio

CDMO specializing in the process development and GMP manufacturing of biologics as well as cell therapy products using microbial and mammalian expression systems. Services:

• Cell line development

• Cell bank cGMP manufacturing and characterization

• Analytical methods development, qualification, and validation

• Scale-up and cGMP supply for clinical trials

• Process characterization & validation

• Commercial supply

• Drug Substance and Drug Product testing and release

• Drug Substance and Drug Product stability studies

• Formulation development

• Comparability studies

• Reference standard manufacturing

• Fill and Finish for DP (with partners)

3P BIOPHARMACEUTICALS

Carmen Martínez Rodríguez, BD [email protected] Technological Park. 13 Louis Proust Street, 47151 Valladolid, Spainwww.linkedin.com/company/53biologics@53Biologics

53Biologics is a contract development and manufacturing organization with extensive ex-perience in cell lines development, bioprocess development and scale-up, and recombi-nant protein batches production.

Cell line development: 53Biologics has proven experience producing a broad catalog of recombinant proteins (monoclonal, fusion, chimeric and fragment antibodies, biosimilars, enzymes, anticoagulants, vaccines...) in a wide range of microbial expression systems such as yeast, fungi or bacteria, mammalian expression systems and insect cells.

Process development: we are experts in the optimization of the production process, pro-duct recovery and purification, ready to be transferred for manufacturing.

Analytics: 53Biologics can implement and validate the analytic methods needed for the characterization of the protein of interest.

Contract productions: The company offers very a high production flexibility, making pos-sible the production of recombinant protein batches at different fermentation volumes, with a high ability to adapt to the method transferred by the client and always meeting the agreed deadlines.

53BIOLOGICS

Maribel Berges, [email protected] Parc Tecnològic, 3 08290 Cerdanyola (Barcelona), [email protected]/company/abilitypharma@AbilityPharma

AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class anticancer compounds causing autophagy via the inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress).

The first drug candidate ABTL0812 is currently in phase 2 clinical trials as first-line thera-py for endometrial cancer and for squamous NSCLC in combination with chemotherapy, followed by maintenance as single-agent. Results for the endometrial cancer group are already available and very promising. The study includes leading institutions in Spain and France. The investigational new drug (IND) is also approved in the US by the FDA with cli-nical trials protocols approved in endometrial, lung and pancreatic cancer, and in China for pancreatic cancer.

ABTL0812 is licensed to SciClone Pharmaceuticals for greater China. The company is cu-rrently seeking to license for the rest of the world or in selected regions.

ABILITY PHARMACEUTICALS

Rocio Arroyo, [email protected] de Recoletos 2,1ºB, 47004 Valladolid, [email protected]/mwlite/company/amadix@AmadixDx

Founded in 2010, Amadix is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is saving lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear, to win the battle against cancer and extend people lives.

The company’s products are oriented to non-invasive early cancer detection, avoiding the complications of existing invasive procedures, as tumor biopsies.

ColoFast, the most advanced product is an innovative blood-based test for colorectal can-cer diagnosis based on a unique combination of cutting-edge biomarkers, which have ne-ver been used in CRC as of today. It is indicated to screen healthy population 50 to 85 years old, for early detection of the tumour and premalignant lesions. ColoFast is expected to be commercialized in 2020. The Company’s test pipeline includes two blood-based tests for early detection of lung and pancreatic cancer.

ADVANCED MARKER DISCOVERY

Robert Fontarnau, Business Development Directorcontact@anapharmbioanalytics.comwww.anapharmbioanalytics.comEncuny 22, 2nd floor, 08038 Barcelona, Spain@Anapharm Bioanalytics

Anapharm Bioanalytics is a bioanalytical contract research organisation (CRO) based in Bar-celona, providing support to the pharmaceutical, biopharmaceutical and generic industries globally, with a focus on full-service bioequivalence studies, as well as high-quality bioa-nalytical services for small and large molecule sample analysis in Phase I-II-III trials and non-clinical studies in compliance with EMA, FDA & ANVISA regulations.

Anapharm has highly trained scientists with over 30 years of experience in the industry. More than 1,500 bioequivalence studies have been performed and over 500 bioanalytical methods are available.

In addition, the firm has undergone 20 inspections from regulatory authorities: 14 studies inspected by FDA (US), 12 studies inspected by EU-GCP authorities and several inspections for GLP certification by EU authorities and ANVISA (Brasil). Such inspections grant its robust regulatory track record, ensuring delivery of consistent, reproducible and reliable data re-quired for international registration.

ANAPHARM BIOANALYTICS

Elena Rivas, [email protected]énova 11, 28004 Madrid, Spain

A4CELL presents a New technology named SPAchip (Suspended Planar-Array Chips) brings you a perfect way to monitorize single cell alive. SPAchips are intracellular silicom micro-chips for monitoring extraordinarily small volumes as a single cell.

Microarray technology, but NOW in a single cell alive! SPAchip device that can be easily internalized in alive cells without affecting cell viability or inducing physiological changes

SPAchip are silicon-based planar chips small enough to reach cell cytoplasm.

Its surface is functionalized by microcontact printing, making them the first intracellular de-vice that can be multiplexed with probes emitting in the same wavelength.

ARRAYS FOR CELL NANODEVICES

Tabatha Bourgois, MedTech Project [email protected] de les Filipines 110 08840 Viladecans (Barcelona), Spainwww.linkedin.com/company/ascil-biopharm@AscilBiopharm

ASCIL Biopharm develops proprietary miniaturized injectable and locally acting therapeu-tics with advanced drug delivery systems (DDS) - formulations and medical devices - to en-hance the safety, effectiveness and convenience of administration of drugs for chronic high burden diseases. The company’s approach leverages the expertise of its highly experienced team, which has pioneered the development of commercial controlled release peptide the-rapeutics, including long-acting biodegradable and self-assembly DDS.

ASCIL has proprietary products for licensing or co-development and collaborates with com-panies and institutions to apply its DDS expertise to their compounds. The company has a portfolio of clinical-ready products for licensing and a pipeline of preclinical stage products for co-development or licensing.

ASCIL PROYECTOS

David Fernández, BD & International Affairs Manager Esther Campos, BD & International Affairs [email protected]/ Diego de León 49, 1º Izq., 28006 Madrid, [email protected]/company/ asociacion-espanola-de-bioempresas@asebio@asebio

Asebio, the Spanish Bioindustry Association, aspires to lead the transformation of our country, Spain, positioning innovation as the engine of its competitiveness and social de-velopment, thus promoting the development of the biotechnological ecosystem as a key element of this paradigm shift. We work to achieve an optimal legal, political and econo-mic environment for the biotechnology industry and act as a catalyst for the innovation opportunities offered by biotechnology.

With over 280 members, Asebio is one of the largest biotechnology associations in Europe and the organizer of the main industry events in Spain such as BioSpain & Asebio Investor Day.

ASEBIO – SPANISH BIOINDUSTRY ASSOCIATION


Lidia Cánovas, General Manager Regulatory [email protected]/ Tarragona, 151 - 157, 08014 Barcelona, Spainwww.linkedin.com/company/asphalion@asphalion

Asphalion is an international Scientific and Regulatory Affairs consultancy, with offices in Barcelona, Madrid, Munich and Amsterdam.

We collaborate with Pharma and Biotech companies facilitating Drug Development and Regulatory Affairs projects for Drugs, Biologics, Biosimilars, ATMPs and Medical Devices. Our involvement ranges from early development, through to registration and post-com-mercialization phases.

Since the company was founded in 2000, we have consistently grown and now have a team of over 90 employees with backgrounds in all areas of life sciences.

Our consultants are experts in their fields and are in direct contact with European agencies for the implementation of new regulatory standards.

Through collaborations with partners in all other continents, we can accelerate your world-wide scientific and regulatory activities. Services:

• Regulatory and Scientific Strategy during Development• Medical and Scientific Writing• Global Submissions• eSubmission and RIM• Life-Cycle Outsourcing• Pharmacovigilance• Promoting the marketing registration of Medical Devices:

Classification strategy, CE Marking and compilation of technical file.

ASPHALION

Jordi Naval, [email protected] Reixac, 4-8, Torre I (PCB) 08028 Barcelona, Spainwww.linkedin.com/company/703143/admin@biocat_en

Biocat is the organization that champions the Healthcare and Life Sciences ecosystem in Catalonia, the most dynamic BioRegion in Spain.

Biocat focuses its strategy on different key points:

• Grow Innovation & Accelerate Business

• Develope Talent & Boost Knowledge

• Position BioRegion Internationally

Set up in 2006 as a public/private foundation, Biocat -along with the government- also drives strategic wide-range policies and projects aimed towards contributing the competi-veness of the sector.

BIOCAT, LA FUNDACIÓ BIOREGIÓ DE CATALUNYA

Mercedes Rodríguez Rojas, Business [email protected] Relva s/n., 36400 O Porriño (Pontevedra), Spainwww.linkedin.com/company/2145255/admin

BIOFABRI is a CDMO. Focused on Human health, which holds EU GMP certification.

Biofabri is an ideal partner for any organization intending to advance their biologic product candidates from development scale to clinical Phase I to III, and commercial supplies capa-bility – Under construction- (Clinical material manufacturing, Aseptic filling, Lyophilization, Labeling-Packaging and Storage)

State-of-art technology, with strong technical, development and manufacturing capabilities and a proven track record.

BIOFABRI is a company of ZENDAL Group (www.zendal.com). Focus on Biotechnology and is engaged in the development, manufacturing and marketing of biological and pharma-ceutical products for human and animal health.

• cGMP Master and Working Seed Lots of cells, Virus and Bacteria.• GMP Upstream & Downstream processes. • Wide capacity for aseptic filling. • Lyophilization• Vaccines formulation.• cGMP manufacture of batches for clinical Trails. • Stability testing of seed lots, intermediates and finished products. In-use stability studies. • Packaging. • Biological and sterile products release. • GDP Authorization: Storage and Shipment.

BIOFABRI

David Resina, [email protected] Science Park. Baldiri Reixac 15, 08028 Barcelona, Spain www.linkedin.com/company/bioingenium-s-l-@bioingenium

BIOINGENIUM is a CDMO company located in Barcelona that provides recombinant protein production services for biotech and pharma.

BIOINGENIUM is one of the world specialists in PICHIA PASTORIS, we provide a free-dom-to-operate system in combination with strain engineering and proprietary UPSTREAM and DOWNSTREAM processes. We are experts in taking your proteins from the laboratory bench to production scale of grams of protein with the highest quality.

Bioingenium is a flexible and expert partner that makes affordable the path to success of your protein.

BIOINGENIUM

Laurent Nguyen, [email protected] Cientific de Barcelona C/ Baldiri i Reixac, 4-8, 08028 Barcelona, [email protected]/company/bionure@Bionure

An optimal candidate to treat neurodegenerative diseases like multiple sclorosis: this is Bio-nure´s goal with its first drug: BN201. After proving it can protect neurons and promote rem-yelination in model animal, the molecule has completed phase 1 trial in Unitred Kingdom in 48 healthy volunteers. Bionure hopes to launch phase 2 trials in early 2020 to prove the effi-cacy of BN201 in patients who suffers from acute episodes of optic neuritis. The company is currently focusing it efforts on multiple scloris and acute optic neurotic, a rare opthalmolo-gic desease for wich BN201 is designated an orphan drug in Europe and the Unated States. A Spin-off of IDIBAPS and CISC, Bionure was funded in 2009 an based in Barcelona Science Park. Late 2017, the company welcome a first institutional VC investor,Alta Life Science, wich led a serie A round to finance a first clinical phase 1 study recently closed an internal round and a second crowdfunding round to find regulatory and technical preparations for the next step for the next step: phase 2 study.

BIONURE FARMA

Luis Berrade, Associate Director BD EuropeBjörn Kolbe, Sr. BD [email protected] Ballardvale St, Wilmington, MA 01887, United Stateswww.linkedin.com/company/charles-river-laboratories

Charles River provides essential products and services to help pharmaceutical and biote-chnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

From research models all the way through the GMP release of your biopharmaceutical pro-duct, Charles River supports your drug develpment. Every step of the way.

• Research Models and Services

• Discovery Services

• Safety Assessment

• Microbial Solutions

• Biologics Testing Solutions

CHARLES RIVER LABORATORIES

Francisco Morís, Managing [email protected] Ciencias de la Salud, Calle Colegio Santo Domingo Guzmán 33011 Oviedo, Spain

3 drugs in oncology: EC-8042, a first in class transcription reprogramming agent for tumors with genomic instability, including pediatric indications (Ewing, rhabdoid); EC-70124 a next-generation multi-kinase inhibitor, first in class tiple FLT3-PIM-SYK inhibi-tor for AML; and EC-7072, a transcritpion modulator for CLL independent of mutational status and interphase cytogenetics.

ENTRECHEM

Carlos Rubio, Executive [email protected] | [email protected] Industria 29, Pol. Ind. Comte de Sert 08755 Castellbisbal, Barcelona, Spain

Laboratorios Rubio is a family owned healthcare laboratory specialiced in medicines, IVD and some nutraceuticals for low prevalence patologies in the fields of Rheumatology, Car-diovascular, Nephrology, Urology and CNS. Through its international network of partners al-ready exports to 47 countries with 13 more with products in registration. Recent Launchings: LIPOSCALE (ce) an IVD to improve the assesement of cardiovascular risk amd Rubidiet Nefro a food for special medical purpose for patients with CKD.

We are interested in licensing out our products to ROW and licensing in pharma, medical devices and IVD for Spain and LATAM.

More info in our profile for this event and our web page

LABORATORIOS RUBIÓ

Michael Thiele, Managing [email protected] 15 - 3 - 1, 08021 Barcelona, Spainwww.linkedin.com/company/lim-global-consulting-s.l.@LIMExecSearch

LIM global are Life Science experts. From C-level to experienced managers we know and inspire the executives you need. LIM offers excellence in Executive Search, Interim Mana-gement and Consulting services for the biomedical industry.

LIM GLOBAL CONSULTING

Ferran García, Strategy & BD Associate [email protected] [email protected]/ Manuel Pombo Angulo, 28 3ª planta 28050 Madrid, Spainwww.linkedin.com/company/mabxience@mAbxience

Spanish fully-fledged biotech company, with a decade of experience in developing and manufacturing biosimilars.

• Part of the Spanish multinational Insud Pharma, which boasts over 40 years’ experience and has +6,000 professionals based in 40 countries around the world.

• Portfolio with two biosimilar products in the market.

• Various biosimilar development programs underway to be marketed worldwide targe-ting the areas of hematology, oncology, osteoporosis and pediatrics.

• Global Partnership Network of key market leaders in the EU, US, Japan and Emerging Markets.

• Two Large-Scale Commercial Manufacturing Facilities in Spain and Argentina.

MABXIENCE RESEARCH

Marc Martinell, [email protected]. Ernest Lluch 32, 08302 Mataró (Barcelona), Spain

Minoryx Therapeutics S.L is a late clinical stage biotech company focused on the deve-lopment of new therapies for X-ALD, Friedreich’s Ataxia and other orphan CNS diseases, a group of rare diseases with high unmet medical need. The company’s lead program, a differentiated PPAR gamma agonist (leriglitazone; MIN-102) that has applicability in multiple CNS indications, has successfully completed a phase 1 clinical trial and has now completed recruitment in a pivotal phase 2/3 trial for adult X-ALD patients (AMN) and in a phase 2 for Friedreich’s Ataxia. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has opera-tions both in Spain and Belgium. It has raised a total of €50M

MINORYX THERAPEUTICS

Carlos Buesa Arjol, [email protected]/ Sant Ferrán, 74. 08940 Cornellà de Llobregat (Barcelona), Spain

Oryzon is a public clinical stage biopharmaceutical company, leader in the development of epigenetics-based therapies with three programs:

• Vafidemstat (ORY-2001), a CNS optimized LSD1 inhibitor, with four ongoing Phase IIA trials: “ETHERAL”, in mild to moderate AD; “REIMAGINE”, aggressiveness in ADHD, BPD and ASD; “REIMAGINE-AD”, aggressiveness in moderate to servere and AD; and “SA-TEEN”, in RRMS and SPMS.

• Iadademstat (ORY-1001), a selective LSD1 inhibitor, with two ongoing Phase IIA trials: “ALICE”: in AML and “CLEPSIDRA”: in ED-SCLC.

• ORY-3001, a third epigenetic compound, also against LSD1. It is ready to start Phase I in a yet undisclosed indication.

ORYZON GENOMICS

Laura Soucek, [email protected] Carrer de Natzaret, 115, Barcelona 08035, Spainwww.linkedin.com/company/peptomyc

Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek‘s lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- can-cer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek’s lab has shown that the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now aims to further develop the Omomyc peptide – and improved variants – into clinically viable therapeutics for the treatment of cancer patients. First clinical trials in lung and breast cancer patients are planned in 2020.

PEPTOMYC

Heiner Pieper, Vice President Business Development & [email protected]. de los Reyes, 1 - 28770 Colmenar Viejo (Madrid), [email protected]/company/pharmamar@[email protected]/c/pharmamar_official

PharmaMar is a biopharmaceutical company, focused on oncology and committed to re-search and development, which takes inspiration from the sea to discover molecules with an-titumor activity. It is an integrated company that seeks innovative products to provide health-care professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. With subsidiaries in Europe and the United States, PharmaMar develops and commercializes Yondelis® in Europe, along with Aplidin®, approved for the Australian market, also having other clinical-stage programs under development for several types of solid cancers: lurbi-nectedin (PM1183), PM184 and PM14.

PharmaMar fully owns other companies. GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).

PHARMA MAR

Clara Campàs, [email protected] de Gracia, 53 Ático, 08007 Barcelona, Spaines.linkedin.com/company/[email protected]/asabyspartners

Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies. Asabys started operations in 2019 and is currently fundraising its first fund, Sabadell Asabys Health Innovation Investments, with a target size of €75M, with the participation of Banc Sabadell as anchor investor in their strategy to promote the health-care innovation entrepreneurial ecosystem.

SABADELL ASABYS HEALTH INNOVATION INVESTMENTS

Joan Perelló, [email protected]. Edificio Europa. 2º piso. Ctra Valldemossa km 7.4, 07121 Palma, Spaines.linkedin.com/company/sanifit-laboratoris@SanifitLabs

Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressi-ve vascular calcification disorders, with SNF472 as its lead compound. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA.

Sanifit’s lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite crystallisation, the final common pathway that leads to vascular calcification. SNF472 is in clinical development for the treatment of calciphylaxis (CUA) in patients undergoing dialysis. In 2018 Sanifit completed a phase II proof-of-concept trial in patients with CUA, which met its primary and secondary endpoints and a phase 3 pivotal study is in preparation. The company is also investigating SNF472 in a Phase 2b proof of concept study (CaLIPSO) to assess its effect on the reduction of cardiovascular calcification progression, with results expected in Q4 2019.

SANIFIT THERAPEUTICS

Raúl Insa, Founder, President and [email protected] de Baldiri Reixac, 4 08028 Barcelona, Spainwww.linkedin.com/company/2354325@sombiotech

SOM BIOTECH

SOM Biotech is a clinical-stage med-tech company focused on Accelerated discovery of the therapies for Neurological Orphan indications. We use the unique approach based on our Computational Artificial Intelligence-based Platform and Scientific Expertise of our Team.

We apply this approach for:

Proprietary pipeline:

• Asset for TTR-Amyloidosis was licensed to a world-wide company based in NY after Phase 2a

• Huntington/Tardive Dyskinesia - Phase 2a finished

• Adrenoleukodystrophy - ready for Phase 2a

• Phenylketonuria and Niemann-Pick - Pre-clinical

• More than 15 compounds - early stage

Our partners, to help them with:

• Identification of new indications for their drugs for life cycle management;

• Identification of effective drugs within any therapeutic area for Pipeline expansion.

Natalia Elizalde, Business Development [email protected] Mikeletegi 81, Parque Científico y Tecnológico de Gipuzkoa 20009 San Sebastián, Gipuzkoa, Spainwww.linkedin.com/company/vivebiotech

VIVEbiotech is a company fully specialized in lentiviral vectors.

As a GMP Contract Development and Manufacturing Organization (CDMO), we are spe-cialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing. VIVEbiotech has experience in manufacturing lentiviral vectors for di-fferent applications such as cancer immune-cell therapy projects (CAR-Ts/TCRs…) and rare diseases, among others.

Currently, we are manufacturing lentiviral vectors for Europe, US and Australia being highly flexible in terms of technical adaptation.

Additionally, VIVEbiotech is working on improved producer cell line development, new pseudo-typing strategies and the development of its own worldwide licensed technology: a non-integrative episomal stable lentiviral vector (LENTISOMA).

VIVEBIOTECH

Jonatan Rapaport, Business Development [email protected] Parque Científico de Madrid, PTM C/ Santiago Grisolía, 2. 28760 Tres Cantos, Madrid, Spainwww.linkedin.com/company/2639067@Vivotecnia

Vivotecnia is a fully independent European toxicology safety contract research organization (CRO) with headquarters based in Madrid, Spain. Our lab was founded in 2000. We offer services to support preclinical product development for pharmaceutical and biotech com-panies and product safety studies for the cosmetic, chemical and agrochemical, food and tobacco industries from around the world.

Our state-of-the-art facilities are GLP-accredited, and the company is managed under the ISO 9001:2008 system. Vivotecnia relies on a strong process-driven environment focused on achieving the highest quality standards on tight deadlines and at competitive prices.

Our design and implementation of state-of-the-art information technologies further enhan-ce performance and delivery. Our animal units house rodents, dogs, rabbits, minipigs and nonhuman primates. Our highly qualified study management team, with lengthy experience in both pharmaceutical and CRO industries, fully understands the challenges you face and is committed to providing the knowledge, advice and high-quality service you expect.

VIVOTECNIA RESEARCH


Diego de León, nº 49, 1º Izqda. 28006 MADRID (Spain)

Tels: +34 91 210 93 10 / 74

www.asebio.com

Documents

SPANI SH B O-E BIOI UR N O D P U MB E S HAM E 2 R T 0 1 R